Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average - Here's What Happened

Veru Inc. (NASDAQ:VERU - Get Free Report) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.99 and traded as low as $0.83. Veru shares last traded at $0.87, with a volume of 541,993 shares traded.

Veru Price Performance

The business's 50 day simple moving average is $0.83 and its 200 day simple moving average is $0.99. The company has a market capitalization of $134.67 million, a price-to-earnings ratio of -2.69 and a beta of -0.49.

Veru (NASDAQ:VERU - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. The business had revenue of $3.95 million during the quarter, compared to analysts' expectations of $3.50 million. During the same quarter in the previous year, the company posted ($0.13) EPS. As a group, analysts expect that Veru Inc. will post -0.3 EPS for the current fiscal year.

Institutional Trading of Veru

Several institutional investors and hedge funds have recently modified their holdings of the business. 180 Wealth Advisors LLC purchased a new position in Veru during the first quarter worth $120,000. Choreo LLC acquired a new position in Veru in the 1st quarter valued at about $64,000. Alpine Global Management LLC lifted its holdings in Veru by 21.0% in the 1st quarter. Alpine Global Management LLC now owns 710,000 shares of the company's stock valued at $497,000 after purchasing an additional 122,999 shares in the last quarter. Ikarian Capital LLC acquired a new stake in shares of Veru during the 1st quarter worth about $663,000. Finally, Cetera Advisors LLC acquired a new position in shares of Veru in the first quarter valued at approximately $33,000. Hedge funds and other institutional investors own 47.16% of the company's stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.